KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Acquisitions: 2012-2020

Historic Acquisitions for Travere Therapeutics (TVTX) over the last 5 years, with Dec 2020 value amounting to $95.3 million.

  • Travere Therapeutics' Acquisitions was N/A to $115,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $63.2 million, marking a year-over-year change of. This contributed to the annual value of $95.3 million for FY2020, which is N/A change from last year.
  • Per Travere Therapeutics' latest filing, its Acquisitions stood at $95.3 million for FY2020, which was up 15,392.52% from $615,000 recorded in FY2016.
  • In the past 5 years, Travere Therapeutics' Acquisitions registered a high of $95.3 million during FY2020, and its lowest value of $615,000 during FY2016.
  • For the 1-year period, Travere Therapeutics' Acquisitions averaged around $95.3 million, with its median value being $95.3 million (2020).
  • Data for Travere Therapeutics' Acquisitions shows a maximum YoY tumbled of 98.16% (in 2016) over the last 5 years.
  • Travere Therapeutics' Acquisitions (Yearly) stood at $615,000 in 2016, then followed by $95.3 million in 2020.